Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019.
- DOI
- 10.1093/ofid/ofac053
- Published
- 2022-02-02
- Container
- Open Forum Infect Dis
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/ofid/ofac053,
title = {Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019.},
author = {Streinu-Cercel A and Săndulescu O and Preotescu LL and Kim JY and Kim YS and Cheon S and Jang YR and Lee SJ and Kim SH and Chang I and Suh JH and Lee SG and Kim MR and Chung DR and Kim HN and Streinu-Cercel A and Eom JS.},
year = {2022},
journal = {Open Forum Infect Dis},
doi = {10.1093/ofid/ofac053},
url = {https://doi.org/10.1093/ofid/ofac053}
}RIS
TY - JOUR TI - Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019. AU - Streinu-Cercel A AU - Săndulescu O AU - Preotescu LL AU - Kim JY AU - Kim YS AU - Cheon S AU - Jang YR AU - Lee SJ AU - Kim SH AU - Chang I AU - Suh JH AU - Lee SG AU - Kim MR AU - Chung DR AU - Kim HN AU - Streinu-Cercel A AU - Eom JS. PY - 2022 JO - Open Forum Infect Dis DO - 10.1093/ofid/ofac053 UR - https://doi.org/10.1093/ofid/ofac053 ER -
APA
A, S., O, S., LL, P., JY, K., YS, K., S, C., YR, J., SJ, L., SH, K., I, C., JH, S., SG, L., MR, K., DR, C., HN, K., A, S., & JS., E. (2022). Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019.. Open Forum Infect Dis. https://doi.org/10.1093/ofid/ofac053
Source records
- europe-pmc · retrieved 2026-09-27T02:25:19.607Z